Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing

David M. Kurtz, Michael R. Green, Scott V. Bratman, Florian Scherer, Chih Long Liu, Christian A. Kunder, Kazuhiro Takahashi, Cynthia Glover, Colm Keane, Shingo Kihira, Brendan Visser, Jason Callahan, Katherine A. Kong, Malek Faham, Karen S. Corbelli, David Miklos, Ranjana H. Advani, Ronald Levy, Rodney J. Hicks, Mark HertzbergRobert S. Ohgami, Maher K. Gandhi, Maximilian Diehn, Ash A. Alizadeh

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

Recent studies have shown limited utility of routine surveillance imaging for diffuse large B-cell lymphoma (DLBCL) patients achieving remission. Detection of molecular disease by immunoglobulin high-throughput sequencing (Ig-HTS) from peripheral blood provides an alternate strategy for surveillance. We prospectively evaluated the utility of Ig-HTS within 311 blood and 105 tumor samples from 75 patients with DLBCL, comparing Ig-HTS from the cellular (circulating leukocytes) and acellular (plasma cell-free DNA) compartments of peripheral blood to clinical outcomes and 18fluoro-deoxyglucose positron emission tomography combined with computed tomography (PET/CT; n = 173). Clonotypic immunoglobulin rearrangements were detected in 83% of patients with adequate tumor samples to enable subsequent monitoring in peripheral blood. Molecular disease measured from plasma, compared with circulating leukocytes, was more abundant and better correlated with radiographic disease burden. Before treatment, molecular disease was detected in the plasma of 82% of patients compared with 71% in circulating cells (P = .68). However, molecular disease was detected significantly more frequently in the plasma at time of relapse (100% vs 30%; P = .001). Detection of molecular disease in the plasma often preceded PET/CT detection of relapse in patients initially achieving remission. During surveillance time points before relapse, plasma Ig-HTS demonstrated improved specificity (100% vs 56%, P < .0001) and similar sensitivity (31% vs 55%, P = .4) compared with PET/CT. Given its high specificity, Ig-HTS from plasma has potential clinical utility for surveillance after complete remission.

Original languageEnglish (US)
Pages (from-to)3679-3687
Number of pages9
JournalBlood
Volume125
Issue number24
DOIs
StatePublished - Jun 11 2015

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Immunoglobulins
Cells
Throughput
Plasmas
Monitoring
Blood
Recurrence
Leukocytes
Tumors
Deoxyglucose
Positron emission tomography
Plasma Cells
Positron-Emission Tomography
Neoplasms
Tomography
Imaging techniques
DNA

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Kurtz, D. M., Green, M. R., Bratman, S. V., Scherer, F., Liu, C. L., Kunder, C. A., ... Alizadeh, A. A. (2015). Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood, 125(24), 3679-3687. https://doi.org/10.1182/blood-2015-03-635169

Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. / Kurtz, David M.; Green, Michael R.; Bratman, Scott V.; Scherer, Florian; Liu, Chih Long; Kunder, Christian A.; Takahashi, Kazuhiro; Glover, Cynthia; Keane, Colm; Kihira, Shingo; Visser, Brendan; Callahan, Jason; Kong, Katherine A.; Faham, Malek; Corbelli, Karen S.; Miklos, David; Advani, Ranjana H.; Levy, Ronald; Hicks, Rodney J.; Hertzberg, Mark; Ohgami, Robert S.; Gandhi, Maher K.; Diehn, Maximilian; Alizadeh, Ash A.

In: Blood, Vol. 125, No. 24, 11.06.2015, p. 3679-3687.

Research output: Contribution to journalArticle

Kurtz, DM, Green, MR, Bratman, SV, Scherer, F, Liu, CL, Kunder, CA, Takahashi, K, Glover, C, Keane, C, Kihira, S, Visser, B, Callahan, J, Kong, KA, Faham, M, Corbelli, KS, Miklos, D, Advani, RH, Levy, R, Hicks, RJ, Hertzberg, M, Ohgami, RS, Gandhi, MK, Diehn, M & Alizadeh, AA 2015, 'Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing', Blood, vol. 125, no. 24, pp. 3679-3687. https://doi.org/10.1182/blood-2015-03-635169
Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, Kunder CA et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015 Jun 11;125(24):3679-3687. https://doi.org/10.1182/blood-2015-03-635169
Kurtz, David M. ; Green, Michael R. ; Bratman, Scott V. ; Scherer, Florian ; Liu, Chih Long ; Kunder, Christian A. ; Takahashi, Kazuhiro ; Glover, Cynthia ; Keane, Colm ; Kihira, Shingo ; Visser, Brendan ; Callahan, Jason ; Kong, Katherine A. ; Faham, Malek ; Corbelli, Karen S. ; Miklos, David ; Advani, Ranjana H. ; Levy, Ronald ; Hicks, Rodney J. ; Hertzberg, Mark ; Ohgami, Robert S. ; Gandhi, Maher K. ; Diehn, Maximilian ; Alizadeh, Ash A. / Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. In: Blood. 2015 ; Vol. 125, No. 24. pp. 3679-3687.
@article{b9004ce89bcc44478dcf0677125e4a66,
title = "Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing",
abstract = "Recent studies have shown limited utility of routine surveillance imaging for diffuse large B-cell lymphoma (DLBCL) patients achieving remission. Detection of molecular disease by immunoglobulin high-throughput sequencing (Ig-HTS) from peripheral blood provides an alternate strategy for surveillance. We prospectively evaluated the utility of Ig-HTS within 311 blood and 105 tumor samples from 75 patients with DLBCL, comparing Ig-HTS from the cellular (circulating leukocytes) and acellular (plasma cell-free DNA) compartments of peripheral blood to clinical outcomes and 18fluoro-deoxyglucose positron emission tomography combined with computed tomography (PET/CT; n = 173). Clonotypic immunoglobulin rearrangements were detected in 83{\%} of patients with adequate tumor samples to enable subsequent monitoring in peripheral blood. Molecular disease measured from plasma, compared with circulating leukocytes, was more abundant and better correlated with radiographic disease burden. Before treatment, molecular disease was detected in the plasma of 82{\%} of patients compared with 71{\%} in circulating cells (P = .68). However, molecular disease was detected significantly more frequently in the plasma at time of relapse (100{\%} vs 30{\%}; P = .001). Detection of molecular disease in the plasma often preceded PET/CT detection of relapse in patients initially achieving remission. During surveillance time points before relapse, plasma Ig-HTS demonstrated improved specificity (100{\%} vs 56{\%}, P < .0001) and similar sensitivity (31{\%} vs 55{\%}, P = .4) compared with PET/CT. Given its high specificity, Ig-HTS from plasma has potential clinical utility for surveillance after complete remission.",
author = "Kurtz, {David M.} and Green, {Michael R.} and Bratman, {Scott V.} and Florian Scherer and Liu, {Chih Long} and Kunder, {Christian A.} and Kazuhiro Takahashi and Cynthia Glover and Colm Keane and Shingo Kihira and Brendan Visser and Jason Callahan and Kong, {Katherine A.} and Malek Faham and Corbelli, {Karen S.} and David Miklos and Advani, {Ranjana H.} and Ronald Levy and Hicks, {Rodney J.} and Mark Hertzberg and Ohgami, {Robert S.} and Gandhi, {Maher K.} and Maximilian Diehn and Alizadeh, {Ash A.}",
year = "2015",
month = "6",
day = "11",
doi = "10.1182/blood-2015-03-635169",
language = "English (US)",
volume = "125",
pages = "3679--3687",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "24",

}

TY - JOUR

T1 - Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing

AU - Kurtz, David M.

AU - Green, Michael R.

AU - Bratman, Scott V.

AU - Scherer, Florian

AU - Liu, Chih Long

AU - Kunder, Christian A.

AU - Takahashi, Kazuhiro

AU - Glover, Cynthia

AU - Keane, Colm

AU - Kihira, Shingo

AU - Visser, Brendan

AU - Callahan, Jason

AU - Kong, Katherine A.

AU - Faham, Malek

AU - Corbelli, Karen S.

AU - Miklos, David

AU - Advani, Ranjana H.

AU - Levy, Ronald

AU - Hicks, Rodney J.

AU - Hertzberg, Mark

AU - Ohgami, Robert S.

AU - Gandhi, Maher K.

AU - Diehn, Maximilian

AU - Alizadeh, Ash A.

PY - 2015/6/11

Y1 - 2015/6/11

N2 - Recent studies have shown limited utility of routine surveillance imaging for diffuse large B-cell lymphoma (DLBCL) patients achieving remission. Detection of molecular disease by immunoglobulin high-throughput sequencing (Ig-HTS) from peripheral blood provides an alternate strategy for surveillance. We prospectively evaluated the utility of Ig-HTS within 311 blood and 105 tumor samples from 75 patients with DLBCL, comparing Ig-HTS from the cellular (circulating leukocytes) and acellular (plasma cell-free DNA) compartments of peripheral blood to clinical outcomes and 18fluoro-deoxyglucose positron emission tomography combined with computed tomography (PET/CT; n = 173). Clonotypic immunoglobulin rearrangements were detected in 83% of patients with adequate tumor samples to enable subsequent monitoring in peripheral blood. Molecular disease measured from plasma, compared with circulating leukocytes, was more abundant and better correlated with radiographic disease burden. Before treatment, molecular disease was detected in the plasma of 82% of patients compared with 71% in circulating cells (P = .68). However, molecular disease was detected significantly more frequently in the plasma at time of relapse (100% vs 30%; P = .001). Detection of molecular disease in the plasma often preceded PET/CT detection of relapse in patients initially achieving remission. During surveillance time points before relapse, plasma Ig-HTS demonstrated improved specificity (100% vs 56%, P < .0001) and similar sensitivity (31% vs 55%, P = .4) compared with PET/CT. Given its high specificity, Ig-HTS from plasma has potential clinical utility for surveillance after complete remission.

AB - Recent studies have shown limited utility of routine surveillance imaging for diffuse large B-cell lymphoma (DLBCL) patients achieving remission. Detection of molecular disease by immunoglobulin high-throughput sequencing (Ig-HTS) from peripheral blood provides an alternate strategy for surveillance. We prospectively evaluated the utility of Ig-HTS within 311 blood and 105 tumor samples from 75 patients with DLBCL, comparing Ig-HTS from the cellular (circulating leukocytes) and acellular (plasma cell-free DNA) compartments of peripheral blood to clinical outcomes and 18fluoro-deoxyglucose positron emission tomography combined with computed tomography (PET/CT; n = 173). Clonotypic immunoglobulin rearrangements were detected in 83% of patients with adequate tumor samples to enable subsequent monitoring in peripheral blood. Molecular disease measured from plasma, compared with circulating leukocytes, was more abundant and better correlated with radiographic disease burden. Before treatment, molecular disease was detected in the plasma of 82% of patients compared with 71% in circulating cells (P = .68). However, molecular disease was detected significantly more frequently in the plasma at time of relapse (100% vs 30%; P = .001). Detection of molecular disease in the plasma often preceded PET/CT detection of relapse in patients initially achieving remission. During surveillance time points before relapse, plasma Ig-HTS demonstrated improved specificity (100% vs 56%, P < .0001) and similar sensitivity (31% vs 55%, P = .4) compared with PET/CT. Given its high specificity, Ig-HTS from plasma has potential clinical utility for surveillance after complete remission.

UR - http://www.scopus.com/inward/record.url?scp=84931287940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931287940&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-03-635169

DO - 10.1182/blood-2015-03-635169

M3 - Article

C2 - 25887775

AN - SCOPUS:84931287940

VL - 125

SP - 3679

EP - 3687

JO - Blood

JF - Blood

SN - 0006-4971

IS - 24

ER -